PHIO PHARMACEUTICALS CORP. — Income Charts
1 years of history · ending 2024-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$231K
R&D
$4M
D&A
$2K
Operating Income
$-7M
EBITDA
$-7M
Interest Expense
—
Other Income/Expense
—
Pretax Income
—
Tax Provision
$0
Net Income
$-7M
Operating Margin
-3197.8%
Net Margin
-3095.2%
Effective Tax Rate
—
DTA Valuation Allowance
$337K
Tax Credit Carryforwards
$5K
NOL Carryforwards
$26K
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
10.6%
Operating Lease Cost
$58K
Revenue YoY Variation
2987.5%
Income YoY Variation
31.8%